This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Temodex

Double Bond Pharmaceutical AB

Description: Temodex is a locally acting form of temozolomide. The drug is a powder for preparation of a gel that can be administered locally during surgery.

Deal Structure: Double Bond and RI PCP
In October 2015, Double Bond Pharmaceutical acquired global marketing rights for Temodex with the exception of the Eurasian Economic Union (Russia, Belarus, Kazakhstan, the Republic of Armenia, the Kyrgyz Republic) and Ukraine.


Temodex News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug